Background Ulcerative colitis (UC) is defined by persistent inflammatory processes within
the gastrointestinal tract of uncertain etiology. Current therapeutic approaches are limited in …

Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory bowel disease
characterized by inflammation, intestinal barrier injury, and imbalance of gut microbiota …

Reactive oxygen species (ROS), immune dysregulation-induced inflammatory outbreaks
and microbial imbalance play critical roles in the development of inflammatory bowel …

Inflammatory bowel disease (IBD) is an incurable disease of the gastrointestinal tract with a
lack of effective therapeutic strategies. The proinflammatory microenvironment plays a …

Intestinal inflammation, such as ulcerative colitis (UC), is a condition in which there is
chronic or recurring inflammation of the gastrointestinal tract. Designing safe, effective, and …

Probiotic-based therapy for ulcerative colitis (UC) is a novel and promising approach that
has gained much popularity in recent years. However, probiotics may be easily captured …

Intestinal commensal microbiota dysbiosis and immune dysfunction are significant
exacerbating factors in inflammatory bowel disease (IBD). To address these problems …

Background Reactive oxygen species (ROS) overproduction and excessive hypoxia play
pivotal roles in the initiation and progression of ulcerative colitis (UC). Synergistic ROS …

Nanozymes are nanomaterials with enzyme-like activities, which have been developed for
inflammatory disease therapy by reactive oxygen species (ROS) scavenging. The …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …